Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin. Issue 1 (23rd October 2018)

• Record Type: Journal Article
• Authors: Chihara, Dai; Wong, Shannon; Feldman, Tatyana; Fanale, Michelle A.; Sanchez, Larysa; Connors, Joseph M.; Savage, Kerry J.; Oki, Yasuhiro
• Is Part Of: Hematological oncology. Volume 37:Issue 1(2019)
• Page Start: 35
• Page End: 38
• Publication Date: 2018-10-23
• Subjects: anaplastic large cell lymphoma -- brentuximab vedotin -- relapse -- transplant; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2560
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: Brentuximab vedotin (BV) is an anti‐CD30 antibody‐drug conjugate that is highly effective in patients with relapsed/refractory anaplastic large cell lymphoma (ALCL). However, survival outcomes following suboptimal response or subsequent relapse are not well known. We conducted a multicenter study analyzing outcomes of patients with relapsed/refractory ALCL who have received BV with a secondary focus on survival after progression following BV. A total of 56 patients were treated with BV for relapsed or refractory ALCL. The overall response rate to BV was 73% with complete response (CR) rate of 46%. The median failure‐free survival and overall survival (OS) after BV were 15.5 month and not reached, respectively. The median duration of response was 27.6 months in patients who achieved CR by BV, while the median OS of those who did not achieve CR by BV was 9.5 months. There was no significant difference in OS between those who underwent stem cell transplant (SCT) and those who did not in patients who achieved CR after BV. However, if patients were in PR after BV, SCT was associated with significantly longer OS. Thirty patients experienced progressive disease on BV or required a subsequent treatment. The median OS after BV failure was 2.9 months with 2‐year OS of 27.1%. There were seven long‐term survivors (≥12 months) following failure. After an adequate response to subsequent salvage therapy, five patients underwent subsequent SCT (three allogeneic and two autologous), four of which were long‐term survivors (17+, 25+, 32+, and 50+ months). In conclusion, BV failure is associated with a poor outcome in patients with ALCL, which defines a small but important group with unmet need. SCT may have benefit in patients with relapsed/refractory ALCL who failed BV.